Sinopharm Accord(SZ:000028)2025-01-17 11:05Financial Projections - The estimated net profit for 2024 is projected to be between 56,100 million and 76,000 million CNY, representing a decline of 52.48% to 64.92% compared to the previous year[4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 49,700 million and 69,600 million CNY, reflecting a decrease of 54.59% to 67.58% year-over-year[4]. - The expected basic earnings per share is between 1.01 CNY and 1.37 CNY, down from 2.87 CNY in the same period last year[4]. - The company plans to recognize an impairment provision for goodwill and intangible assets between 87,600 million and 107,000 million CNY, which is expected to reduce net profit attributable to shareholders by 50,500 million to 61,800 million CNY[6][7]. - An additional impairment provision for receivables and inventory is estimated to be between 9,400 million and 14,100 million CNY, potentially reducing net profit by 5,000 million to 7,500 million CNY[8]. Retail Strategy - The company aims to enhance retail performance by adjusting its structural layout and implementing targeted strategies for individual stores[10]. - The focus will be on optimizing product structure and increasing the proportion of self-owned brands and centralized procurement sales to enhance competitiveness[10]. - The company is committed to driving digital innovation and improving process efficiency to support high-quality development in the retail sector[10]. Financial Data Caution - The company acknowledges the uncertainty in the preliminary financial data and advises investors to exercise caution[11]. - The financial data presented is based on preliminary estimates and has not been audited by the accounting firm[11].